Akhali Mzera Eye Clinic
Tbilisi, Georgia
NCT Number: NCT04758598
The objective of this study is to compare the long-term (6 months) effects of Direct Selective Laser Trabeculoplasty (DSLT) treatment and SLT (Selective Laser Trabeculoplasty) treatment on corneal endothelial cell counts and corneal thickness.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Not applicable
Tbilisi, Georgia
Rational:
SLT has known transient effect on corneal endothelial cell (CEC) counts yet no data is yet available with DSLT.
This study is relevant as the DSLT treatment area is at the limbus: CEC progenitor site
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
Time frame: 6 months
Central corneal thickness will be assessed by pachymetry
Time frame: 6 months
Corneal endothelial cell count will be assessed with specular microscopy
BelkinVision
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07082816
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsNCT06851546
Eye Diseases, Glaucoma
Rochester, Minnesota, United States
View Trial DetailsNCT04060758
Eye Diseases, Glaucoma
Castle Hill, New South Wales, Australia
View Trial DetailsNCT06441643
Eye Diseases, Glaucoma
Garden Grove, California, United States
View Trial Details